{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions;\n\nObjective Tumor Response \"of more than 4 months\" was counted toward the Disease Control Rate.","groups":[{"description":"Patients receive oral AZD0530 once daily in the absence of disease progression or unacceptable toxicity.\n\nsaracatinib: Given orally","id":"OG000","title":"Arm I AZD0530"}],"paramType":"NUMBER","populationDescription":"Patients who had partial response, complete response or stable disease","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"participants"}